GRO Biosciences has developed a synthetic biology platform that utilizes non-standard amino acids (NSAAs) to enhance protein therapeutics, improving their potency, stability, and immunogenicity. The platform specifically targets the limitations of traditional protein therapies, enabling more effective treatments for autoimmune diseases.
Funding
$91.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ABFounders
Product
Problem
Traditional protein therapeutics are limited by the inherent properties of the 20 standard amino acids, which can restrict their potency, stability, and immunogenicity, hindering their effectiveness in treating diseases like autoimmune disorders. These limitations pose challenges in developing targeted and well-tolerated therapies.
Solution
GRO Biosciences has developed a synthetic biology platform that expands the genetic code to incorporate non-standard amino acids (NSAAs) into protein therapeutics, overcoming the limitations of traditional protein therapies. The GRO platform enables precise control over protein glycosylation through ProGly™ NSAAs, allowing for the creation of novel protein structures and functionalities. By incorporating NSAAs, GRO Biosciences can enhance protein therapeutics to improve their potency, stability, and reduce immunogenicity. This approach allows for the development of more effective and targeted treatments, particularly in areas such as reversing autoimmunity and eliminating unwanted immune responses.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing advanced protein therapeutics for autoimmune diseases and other conditions requiring improved protein properties.
Features
- Proprietary platform for incorporating non-standard amino acids (NSAAs) into proteins.
- ProGly™ NSAAs for precise control over protein glycosylation.
- Enhanced protein stability and reduced immunogenicity through NSAA incorporation.
- Ability to re-educate the immune system to reverse autoimmune processes.
- Development of novel protein therapeutics with improved potency.